Waters Corporation (0LTI.L)
USD 370.56
(-0.36%)
USD 370.56
(-0.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 943.51 Million USD | 5.28% |
| 2022 | 840.58 Million USD | 4.75% |
| 2021 | 802.46 Million USD | 13.82% |
| 2020 | 705.06 Million USD | 2.56% |
| 2019 | 687.43 Million USD | -0.08% |
| 2018 | 688.01 Million USD | 0.58% |
| 2017 | 684.03 Million USD | 5.54% |
| 2016 | 648.1 Million USD | 3.79% |
| 2015 | 624.41 Million USD | -1.05% |
| 2014 | 631.06 Million USD | 4.58% |
| 2013 | 603.41 Million USD | 2.78% |
| 2012 | 587.1 Million USD | -0.84% |
| 2011 | 592.09 Million USD | 9.62% |
| 2010 | 540.13 Million USD | 6.07% |
| 2009 | 509.21 Million USD | -2.84% |
| 2008 | 524.1 Million USD | 6.3% |
| 2007 | 493.04 Million USD | 11.95% |
| 2006 | 440.4 Million USD | 11.01% |
| 2005 | 396.72 Million USD | 8.71% |
| 2004 | 364.92 Million USD | 7.25% |
| 2003 | 340.26 Million USD | 8.82% |
| 2002 | 312.68 Million USD | -21.52% |
| 2001 | 398.44 Million USD | 25.16% |
| 2000 | 318.34 Million USD | 8.91% |
| 1999 | 292.3 Million USD | 8.66% |
| 1998 | 269 Million USD | -0.07% |
| 1997 | 269.2 Million USD | 43.8% |
| 1996 | 187.2 Million USD | 12.16% |
| 1995 | 166.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 219.13 Million USD | -1.76% |
| 2024 Q3 | 217.43 Million USD | 0.46% |
| 2024 Q2 | 216.42 Million USD | -1.23% |
| 2023 Q2 | 239.64 Million USD | 5.98% |
| 2023 Q1 | 226.12 Million USD | 0.93% |
| 2023 Q4 | 223.05 Million USD | -7.39% |
| 2023 FY | 884.95 Million USD | 5.28% |
| 2023 Q3 | 240.85 Million USD | 0.51% |
| 2022 Q3 | 209.44 Million USD | 0.95% |
| 2022 Q4 | 224.03 Million USD | 6.97% |
| 2022 FY | 840.58 Million USD | 4.75% |
| 2022 Q1 | 199.62 Million USD | -8.46% |
| 2022 Q2 | 207.48 Million USD | 3.94% |
| 2021 Q4 | 218.08 Million USD | 11.1% |
| 2021 FY | 802.46 Million USD | 13.82% |
| 2021 Q2 | 204.97 Million USD | 11.93% |
| 2021 Q3 | 196.29 Million USD | -4.24% |
| 2021 Q1 | 183.12 Million USD | -6.3% |
| 2020 Q3 | 173.05 Million USD | 14.44% |
| 2020 Q2 | 151.22 Million USD | -18.41% |
| 2020 FY | 705.06 Million USD | 2.56% |
| 2020 Q1 | 185.34 Million USD | 2.51% |
| 2020 Q4 | 195.43 Million USD | 12.93% |
| 2019 Q3 | 162.98 Million USD | -5.22% |
| 2019 FY | 687.43 Million USD | -0.08% |
| 2019 Q1 | 171.68 Million USD | -6.34% |
| 2019 Q2 | 171.96 Million USD | 0.16% |
| 2019 Q4 | 180.8 Million USD | 10.93% |
| 2018 Q4 | 183.29 Million USD | 11.57% |
| 2018 FY | 688.01 Million USD | 0.58% |
| 2018 Q2 | 173.89 Million USD | 4.41% |
| 2018 Q1 | 166.54 Million USD | -10.24% |
| 2018 Q3 | 164.28 Million USD | -5.52% |
| 2017 Q3 | 170.65 Million USD | 3.54% |
| 2017 FY | 684.03 Million USD | 5.54% |
| 2017 Q4 | 185.55 Million USD | 8.73% |
| 2017 Q1 | 163 Million USD | -1.42% |
| 2017 Q2 | 164.82 Million USD | 1.11% |
| 2016 Q4 | 165.34 Million USD | 5.48% |
| 2016 Q2 | 164.57 Million USD | 1.94% |
| 2016 Q1 | 161.43 Million USD | 1.15% |
| 2016 FY | 648.1 Million USD | 3.79% |
| 2016 Q3 | 156.75 Million USD | -4.75% |
| 2015 Q1 | 151.17 Million USD | -7.4% |
| 2015 Q3 | 157.93 Million USD | 1.42% |
| 2015 Q4 | 159.59 Million USD | 1.05% |
| 2015 FY | 624.41 Million USD | -1.05% |
| 2015 Q2 | 155.71 Million USD | 3.0% |
| 2014 Q1 | 154.02 Million USD | -3.9% |
| 2014 Q2 | 161.55 Million USD | 4.89% |
| 2014 Q3 | 152.23 Million USD | -5.77% |
| 2014 Q4 | 163.25 Million USD | 7.24% |
| 2014 FY | 631.06 Million USD | 4.58% |
| 2013 FY | 603.41 Million USD | 2.78% |
| 2013 Q4 | 160.28 Million USD | 9.27% |
| 2013 Q1 | 146.36 Million USD | -2.14% |
| 2013 Q3 | 146.68 Million USD | -2.27% |
| 2013 Q2 | 150.09 Million USD | 2.55% |
| 2012 Q1 | 142.95 Million USD | -6.14% |
| 2012 Q2 | 152.08 Million USD | 6.39% |
| 2012 Q3 | 145.5 Million USD | -4.33% |
| 2012 Q4 | 149.56 Million USD | 2.79% |
| 2012 FY | 587.1 Million USD | -0.84% |
| 2011 Q1 | 141.87 Million USD | -2.92% |
| 2011 FY | 592.09 Million USD | 9.62% |
| 2011 Q3 | 146.95 Million USD | -2.65% |
| 2011 Q4 | 152.3 Million USD | 3.64% |
| 2011 Q2 | 150.95 Million USD | 6.4% |
| 2010 Q2 | 130.33 Million USD | 0.72% |
| 2010 FY | 540.13 Million USD | 6.07% |
| 2010 Q4 | 146.14 Million USD | 8.87% |
| 2010 Q3 | 134.23 Million USD | 2.99% |
| 2010 Q1 | 129.41 Million USD | -2.27% |
| 2009 Q4 | 132.41 Million USD | 6.18% |
| 2009 FY | 509.21 Million USD | -2.84% |
| 2009 Q2 | 131.98 Million USD | 9.89% |
| 2009 Q3 | 124.7 Million USD | -5.52% |
| 2009 Q1 | 120.1 Million USD | -7.56% |
| 2008 FY | 524.1 Million USD | 6.3% |
| 2008 Q4 | 129.93 Million USD | 0.14% |
| 2008 Q3 | 129.75 Million USD | -4.95% |
| 2008 Q2 | 136.51 Million USD | 6.74% |
| 2008 Q1 | 127.89 Million USD | 2.24% |
| 2007 Q1 | 114.75 Million USD | -1.66% |
| 2007 Q3 | 129.72 Million USD | 5.07% |
| 2007 Q2 | 123.47 Million USD | 7.6% |
| 2007 Q4 | 125.09 Million USD | -3.57% |
| 2007 FY | 493.04 Million USD | 11.95% |
| 2006 FY | 440.4 Million USD | 11.01% |
| 2006 Q2 | 110 Million USD | 4.0% |
| 2006 Q1 | 105.77 Million USD | 3.07% |
| 2006 Q3 | 107.93 Million USD | -1.88% |
| 2006 Q4 | 116.69 Million USD | 8.11% |
| 2005 FY | 396.72 Million USD | 8.71% |
| 2005 Q2 | 100.61 Million USD | 2.02% |
| 2005 Q3 | 94.86 Million USD | -5.71% |
| 2005 Q4 | 102.62 Million USD | 8.17% |
| 2005 Q1 | 98.62 Million USD | -3.9% |
| 2004 FY | 364.92 Million USD | 7.25% |
| 2004 Q1 | 96.69 Million USD | 6.25% |
| 2004 Q2 | 75.4 Million USD | -22.02% |
| 2004 Q3 | 90.19 Million USD | 19.61% |
| 2004 Q4 | 102.62 Million USD | 13.78% |
| 2003 Q4 | 91.01 Million USD | 9.62% |
| 2003 FY | 340.26 Million USD | 8.82% |
| 2003 Q3 | 83.02 Million USD | -0.56% |
| 2003 Q1 | 82.73 Million USD | 96.76% |
| 2003 Q2 | 83.49 Million USD | 0.93% |
| 2002 Q4 | 42.04 Million USD | -54.36% |
| 2002 Q3 | 92.11 Million USD | -1.59% |
| 2002 Q2 | 93.6 Million USD | 10.56% |
| 2002 Q1 | 84.66 Million USD | -46.62% |
| 2002 FY | 312.68 Million USD | -21.52% |
| 2001 Q1 | 86.56 Million USD | 3.8% |
| 2001 Q2 | 80.68 Million USD | -6.8% |
| 2001 Q4 | 158.61 Million USD | 97.13% |
| 2001 Q3 | 80.46 Million USD | -0.27% |
| 2001 FY | 398.44 Million USD | 25.16% |
| 2000 Q4 | 83.39 Million USD | 6.56% |
| 2000 Q1 | 78.47 Million USD | -0.29% |
| 2000 Q2 | 78.21 Million USD | -0.33% |
| 2000 Q3 | 78.26 Million USD | 0.06% |
| 2000 FY | 318.34 Million USD | 8.91% |
| 1999 Q1 | 70.2 Million USD | -1.96% |
| 1999 FY | 292.3 Million USD | 8.66% |
| 1999 Q4 | 78.7 Million USD | 8.4% |
| 1999 Q3 | 72.6 Million USD | 2.54% |
| 1999 Q2 | 70.8 Million USD | 0.85% |
| 1998 FY | 269 Million USD | -0.07% |
| 1998 Q4 | 71.6 Million USD | 9.82% |
| 1998 Q3 | 65.2 Million USD | -3.12% |
| 1998 Q2 | 67.3 Million USD | 3.54% |
| 1998 Q1 | 65 Million USD | 0.31% |
| 1997 Q3 | 105.3 Million USD | 112.73% |
| 1997 Q4 | 64.8 Million USD | -38.46% |
| 1997 Q1 | 49.6 Million USD | -3.13% |
| 1997 FY | 269.2 Million USD | 43.8% |
| 1997 Q2 | 49.5 Million USD | -0.2% |
| 1996 FY | 187.2 Million USD | 12.16% |
| 1996 Q3 | 48.5 Million USD | 6.83% |
| 1996 Q2 | 45.4 Million USD | 7.84% |
| 1996 Q1 | 42.1 Million USD | -9.07% |
| 1996 Q4 | 51.2 Million USD | 5.57% |
| 1995 Q3 | 41.1 Million USD | 2.49% |
| 1995 Q1 | 39.2 Million USD | 0.0% |
| 1995 FY | 166.9 Million USD | 0.0% |
| 1995 Q4 | 46.3 Million USD | 12.65% |
| 1995 Q2 | 40.1 Million USD | 2.3% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -281.521% |
| Dynavax Technologies Corporation | 219.14 Million USD | -330.545% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -78.355% |
| Perrigo Company plc | 1.52 Billion USD | 38.272% |
| Illumina, Inc. | 3.81 Billion USD | 75.255% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 90.799% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -109.209% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 97.676% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 54.042% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -681.983% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 66.486% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2012.336% |
| Biogen Inc. | 5.2 Billion USD | 81.873% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -312.593% |
| Evolus, Inc. | 189.75 Million USD | -397.219% |
| Adicet Bio, Inc. | 152.03 Million USD | -520.58% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -562.289% |
| bluebird bio, Inc. | 240.23 Million USD | -292.752% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -247.013% |
| FibroGen, Inc. | 398.11 Million USD | -136.997% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 55.389% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -6683.187% |
| Homology Medicines, Inc. | 9.87 Million USD | -9454.603% |
| Geron Corporation | 70.44 Million USD | -1239.443% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 47.584% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -120.628% |
| Myriad Genetics, Inc. | 600.1 Million USD | -57.227% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -835.778% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -71.061% |
| Zoetis Inc. | 2.76 Billion USD | 65.876% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1845.316% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 13.39% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 45.97% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 80.24% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -2309.82% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -21.028% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -242.235% |
| Verastem, Inc. | 92.08 Million USD | -924.626% |
| Nektar Therapeutics | 190.9 Million USD | -394.239% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -98.068% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -7671.329% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 30.665% |
| OPKO Health, Inc. | 574.68 Million USD | -64.18% |
| Exelixis, Inc. | 1.58 Billion USD | 40.539% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 40.901% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -155.965% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1592.225% |
| uniQure N.V. | 285.08 Million USD | -230.959% |
| Imunon, Inc. | 21.03 Million USD | -4386.437% |
| Blueprint Medicines Corporation | 722.86 Million USD | -30.525% |
| Insmed Incorporated | 949.26 Million USD | 0.605% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -215.222% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -130.798% |
| TG Therapeutics, Inc. | 198.47 Million USD | -375.383% |
| Incyte Corporation | 1.19 Billion USD | 20.746% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 9.625% |